Lee Saladino’s practice draws extensively on her U.S. legal background, which primarily involved representing U.S. financial institutions acting as initial purchasers or managing underwriters in connection with Rule 144A / Regulation S high-yield offerings of debt securities by U.S. issuers, or as lead arrangers and administrative agents in connection with the arrangement and syndication of senior secured credit facilities for U.S. and foreign borrowers for purposes of leveraged acquisitions (with an emphasis on acquisition financing for private equity sponsors) or working capital financing. Recent capital markets transactions include representing:
- Molecular Partners in its IPO on the SIX Swiss Exchange, which was Europe’s second largest biotech IPO of 2014, and the first biotech IPO in Switzerland in five years;
- Credit Suisse in its inaugural and subsequent issuances of write-down bonds totaling approximately CHF 6 billion, which qualify as either additional tier 1 or tier 2 capital under the Basel III standards and the Swiss capital adequacy rules;
- GE Capital Swiss Funding as selling shareholder in GE (now Cembra) Money Bank’s IPO on the SIX Swiss Exchange, which was the only IPO in Switzerland in 2013;
- UBS in its inaugural and subsequent offerings of USD 4,000,000,000 of loss-absorbing notes totaling approximately USD 10,000,000,000, which qualify as both tier 2 capital under Basel III standards and progressive capital component under the new Swiss capital adequacy rules;
- Credit Suisse in its offering of CHF 3,802,944,000 of mandatory and contingent convertible securities;
- Evolva in its rights offering of 52,214,472 shares; and
- Autoneum in its listing on the SIX Swiss Exchange in connection with Rieter’s distribution of Autoneum’s shares to Rieter’s shareholders.
Lee Saladino was recently listed in the Leaders in their Field section of the 2013 edition of Chambers Global as a capital markets expert.
